Iranian media reports confirm high-stakes talks between the U.S. and Iran are scheduled for Friday in Oman, a familiar neutral ground, as regional hostilities escalate and international scrutiny intensifies over Tehran's harsh response to recent protests.
Wall Street grapples with a pronounced sector rotation out of high-flying technology names, driving volatility across major indices. Amid the shift, analyst calls highlight potential value in energy, consumer discretionary, and select fintech stocks for February 4, 2026.
The commercial real estate data giant CoStar Group faces mounting pressure as hedge fund D.E. Shaw joins Third Point in demanding board changes and a review of its costly Homes.com venture, signaling a major proxy battle ahead.
Industrial technology conglomerate Fortive (NYSE:FTV) reported fourth-quarter revenue and profit that topped analyst forecasts, driven by strong execution and disciplined capital allocation, even as broader market headwinds loom.
French specialty chemicals leader Arkema and China's Senior Technology have entered a comprehensive collaboration to fast-track the development and industrial-scale production of advanced materials for lithium-ion batteries, targeting the booming electric vehicle and energy storage markets.
The pharmaceutical giant AbbVie projects profits exceeding analyst expectations for 2026, buoyed by the stellar performance of its newer immunology drugs Skyrizi and Rinvoq, which are successfully offsetting the decline of its former top-seller Humira.
Wabash National Corporation reported fourth-quarter revenue that surpassed Wall Street expectations, yet a sharp year-over-year sales decline and a disappointing forward outlook triggered a significant sell-off, highlighting ongoing challenges in the freight and industrial sectors.
The Reserve Bank of India is fundamentally reshaping its oversight of lenders, moving beyond traditional financial metrics to scrutinize the actual business practices and credit management processes within banks.
The fast-food giant behind KFC and Taco Bell reported quarterly sales of $2.51 billion, topping analyst forecasts, but earnings per share came in just below expectations.
GSK reported robust full-year 2025 results, with sales exceeding £32 billion and profit growth outpacing revenue. Executives outlined a 2026 strategy focused on maximizing recent drug launches, accelerating late-stage pipeline assets, and leveraging technology, while navigating currency headwinds and a profit shift to the second half.
U.S. equity futures edged higher Wednesday after Washington moved to reopen the federal government, shifting investor attention to a heavy slate of corporate earnings led by tech giant Alphabet.
Reynolds Consumer Products (NASDAQ: REYN) reported fourth-quarter sales that surpassed analyst expectations, though a weaker-than-anticipated revenue forecast for the coming quarter highlights ongoing challenges in volume growth for the household staples maker.
The industrial toolmaker reported flat year-over-year sales of $3.68 billion for Q4 2025, missing analyst estimates, though adjusted earnings per share of $1.41 came in nearly 10% above forecasts. The mixed results highlight ongoing challenges in a dynamic market.
Novo Nordisk's stock tumbled sharply after the Danish pharmaceutical giant issued a weaker-than-expected forecast for 2026, citing pricing deals and competitive threats to its blockbuster weight-loss drugs.
Chancellor Friedrich Merz embarks on a pivotal three-nation Gulf tour, signaling Berlin's strategic push to diversify trade and energy partnerships amid global realignment, as both Germany and the Gulf monarchies seek to reduce mutual dependencies.
The search for Savannah Guthrie's 84-year-old mother, Nancy, enters its fourth day with the disturbing emergence of purported ransom notes sent to media outlets, as authorities investigate signs of a forced entry at her Tucson home.
UBS capped a transformative year with a 56% jump in Q4 profit, pushing group invested assets past the $7 trillion milestone for the first time, as its integration of Credit Suisse nears completion.
GSK's annual net profit more than doubled in 2025, fueled by robust sales of HIV, respiratory, and oncology medicines. The results signal a strong recovery for the pharma giant after settling costly U.S. lawsuits related to its discontinued heartburn drug Zantac.
The New York Times Company (NYSE: NYT) reported fourth-quarter revenue of $802.3 million, a 10.4% year-over-year increase that surpassed analyst expectations. While adjusted earnings per share met consensus, the results highlight both the strength of its digital transition and ongoing challenges in monetizing its growing subscriber base.
Johnson Controls International (NYSE: JCI) reported fourth-quarter results that exceeded analyst expectations, with revenue climbing 6.8% year-over-year to $5.80 billion. Adjusted earnings per share of $0.89 also topped estimates, sending the stock sharply higher.
